Guardant Health (NASDAQ: GH) — Perfil da empresa, notícias e dados financeiros
Guardant Health develops cancer-focused blood tests and genomic profiling assays, aiming to improve outcomes in precision oncology.
Guardant Health
Guardant Health is a precision oncology company that develops and commercializes blood tests, tissue assays, and bioinformatics tools for cancer care. The company provides liquid biopsy tests to assist oncologists with treatment selection for advanced cancer, early detection of disease recurrence, and population screening. Its diagnostic portfolio includes tests designed to detect circulating tumor DNA and evaluate actionable genomic alterations across various solid tumors. Guardant Health also collaborates with pharmaceutical partners to accelerate drug development, support clinical trial biomarker evaluation, and co-develop companion diagnostics for targeted therapies globally.
Resumo
Operações
Produtos e/ou serviços de Guardant Health
- Guardant360 Portfolio: Liquid biopsy blood tests, including Guardant360 CDx, providing comprehensive genomic profiling and companion diagnostic insights to guide precision therapy selection for advanced stage cancer patients across broad clinical settings.
- Shield Screening Test: Blood-based screening test designed for primary colorectal cancer detection in average-risk adults, providing a non-invasive alternative to traditional colonoscopy and stool-based screening modalities in routine healthcare settings.
- Guardant Reveal: Blood-based minimal residual disease test engineered to detect circulating tumor DNA following cancer treatment, enabling early detection of recurrence and monitoring response in patients with early-stage cancers.
- Guardant TissueNext: Tissue-based genomic profiling test designed to complement liquid biopsy assays by analyzing solid tumor tissue samples when actionable biomarker identification requires tissue-specific mutational analysis and comprehensive genomic evaluation.
- Guardant Infinity Platform: Next-generation genomic and epigenomic profiling platform providing biopharma partners with advanced multi-omic liquid biopsy capabilities to accelerate clinical trial biomarker evaluation and therapy development.
- BioPharma Solutions: Comprehensive oncology research services partnering with pharmaceutical companies to accelerate targeted drug development, support novel biomarker discovery, and co-develop companion diagnostics for novel anti-cancer therapies.
equipe executiva do Guardant Health
- Helmy EltoukhyCo-Founder, Co-CEO & Chairman
- AmirAli TalasazCo-CEO & Director
- Michael BellChief Financial Officer
- Darya ChudovaChief Technology Officer
- John G. SaiaChief Legal Officer & Corporate Secretary
- Andy AmentSenior Vice President of Operations
- Robert ParksSenior VP & Chief Accounting Officer
- Kumud KaliaChief Information Officer
- Zarak KhurshidVice President of Investor Relations
- Gulshan ShaverSenior VP of Legal Affairs & Chief Compliance Officer
Últimas notícias sobre a Guardant Health
Principais indicadores financeiros
Resultados divulgados pela Guardant Health, em USD.
- Cap. de mercado
- 23,9 bi
- Receita (TTM)
- 1,2 bi
- P/L
- —
- LPA (diluído, TTM)
- -3.5
- Dividend yield
- —
- Margem de lucro
- -38.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 982 mi | -437,2 mi | -416,3 mi | |
| 739 mi | -443,6 mi | -436,4 mi | |
| 563,9 mi | -564,7 mi | -479,4 mi | |
| 449,5 mi | -544,4 mi | -654,6 mi |